M&A Deal Summary

Amgen Acquires Immunex

On July 16, 2002, Amgen acquired life science company Immunex for 16.0B USD

Acquisition Highlights
  • This is Amgen’s 2nd transaction in the Life Science sector.
  • This is Amgen’s 2nd largest (disclosed) transaction.
  • This is Amgen’s 2nd transaction in the United States.
  • This is Amgen’s 1st transaction in Washington.

M&A Deal Summary
Date 2002-07-16
Target Immunex
Sector Life Science
Buyer(s) Amgen
Deal Type Add-on Acquisition
Deal Value 16.0B USD

Target

Immunex

Seattle, Washington, United States
Immunex Corporation is a biopharmaceutical company dedicated to improving lives through immune system science innovation.

Search 192,349 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Amgen

Thousand Oaks, California, United States

website

Category Company
Founded 1980
Sector Life Science
Employees25,200
Revenue 26.3B USD (2022)
DESCRIPTION
Entrance to Amgen's corporate campus in Thousand Oaks, California.
Entrance to Amgen's corporate campus in Thousand Oaks, California.

Amgen is a drug development company focused on discovering, developing, manufacturing and delivering human therapeutics. Amgen uses tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and people's lives. Amgen was founded in 1980 and is based in Thousand Oaks, California.

DEAL STATS #
Overall 2 of 21
Sector (Life Science) 2 of 20
Type (Add-on Acquisition) 2 of 20
State (Washington) 1 of 2
Country (United States) 2 of 16
Year (2002) 1 of 1
Size (of disclosed) 2 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2000-10-17 Kinetix Pharmaceuticals

Medford, Massachusetts, United States

Kinetix Pharmaceuticals, a privately-held Massachussets, USA-based company that specializes in discovering small molecules in the field of protein kinase inhibition.

Buy $170M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2004-03-29 Tularik

San Francisco, California, United States

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. Tularik currently has five drug candidates in clinical trials. In the cancer area, Tularik is currently conducting a pivotal study of T67 for the treatment of hepatocellular carcinoma and Phase 2 trials with T607 for the treatment of gastric and esophageal cancer. T487, for the treatment of inflammatory diseases, and T131, for the treatment of type 2 diabetes, are in Phase 2 trials to evaluate safety and pharmacokinetic parameters.

Buy $1.3B
Mergr

Product

Company

Legal